Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| AKRN Scientific Consulting, S.L. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
This is a BlueDop Vascular Expert System (BVE) Post-Market Clinical Follow-Up (PMCF) study. The primary objective of the study is to assess the clinical applicability and diagnostic accuracy of the BVE device in subjects who require an arterial duplex test due to suspected peripheral arterial disease (PAD).
The BVE device is intended to assess mean peripheral pressure, vascular reserve, Cuff free Ankle Brachial Index (ABIm), and assess the presence or absence of hemodynamically significant arterial disease. By converting Doppler shifts to a blood pressure measurement, BVE can be used to monitor PAD in a non-invasive manner without confounding by arterial calcification.
This is a post-market, interventional, prospective, multi-center, open-label, non-randomized, single-arm clinical investigation designed to evaluate the clinical equivalence of BVE to arterial Duplex in a group of patients referred for evaluation of PAD of the limbs when performed by a vascular specialist. Moreover, the evaluation of the clinical performance including inter-operator variability and BVE non-diagnostic rate will be also carried out as exploratory variables.
Primary objective:
Evaluate the clinical equivalence (assessment of accuracy) of BVE as binary result (either presence or absence of significant peripheral arterial disease) compared to arterial duplex ultrasound in a group of patients referred for evaluation of PAD of the lower limbs when performed by a vascular specialist.
Secondary objectives:
Evaluate the clinical equivalence (assessment of accuracy) of BVE as binary result (either presence or absence of significant peripheral arterial disease) compared to ankle brachial pressure index (ABPI) in a group of patients referred for evaluation of PAD of the lower limbs when performed by a vascular specialist.
Assess the safety of the BVE device.
Exploratory objectives:
Evaluation of the BVE System for clinical performance including time needed to perform BVE, inter-operator variability and number of BVE non-diagnostic tests.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| BlueDop Vascular Expert (BVE) | PAD assessment with BVE |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BVE | Device | Participants will undergo BVE evaluation for assessing Peripheral Arterial Disease (PAD) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Determination of Presence or Absence of Significant PAD With BVE and Arterial Duplex | Evaluation of clinical equivalence through a binary result (either presence or absence of significant PAD) in BVE compared to a binary summary of the arterial duplex. Significant PAD is established with Duplex ultrasound when peak systolic velocity ratio (PSVR) is greater than 3 for any one level, or, if patients have multi-level disease, PSVR ≥ 2 at more than one level (i.e. sfa, pop) | 1 day |
| Measure | Description | Time Frame |
|---|---|---|
| Determination of Presence or Absence of Significant PAD With BVE and ABPI | Evaluation of clinical equivalence through a binary result (either presence or absence of significant PAD) in BVE compared to a binary summary of ABPI. Significant PAD is established when ABPI index is <0.8. | 1 day |
| Number and Risk-classification of Adverse Events (AEs) and Serious Adverse Events (SAEs) |
| Measure | Description | Time Frame |
|---|---|---|
| Time Spent for Arterial Duplex, BVE and ABPI Vascular Assessment | Comparison of the time to perform a vascular assessment using arterial duplex, BVE, and ABPI (when available). | 1 day |
| Determination of Presence or Absence of Significant PAD With BVE by Vascular and Non-vascular Experts |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients referred for evaluation of PAD of the limbs when performed with duplex by a vascular specialist
Not provided
| Name | Affiliation | Role |
|---|---|---|
| José Ignacio Leal Lorenzo | Clínica Universidad de Navarra | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Los Madroños | Brunete | Madrid | 28690 | Spain | ||
| Hospital de Manises |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | BlueDop Vascular Expert (BVE) | PAD assessment with BVE BVE: Participants will undergo BVE evaluation for assessing Peripheral Arterial Disease (PAD) |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | BlueDop Vascular Expert (BVE) | PAD assessment with BVE BVE: Participants will undergo BVE evaluation for assessing Peripheral Arterial Disease (PAD) |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Determination of Presence or Absence of Significant PAD With BVE and Arterial Duplex | Evaluation of clinical equivalence through a binary result (either presence or absence of significant PAD) in BVE compared to a binary summary of the arterial duplex. Significant PAD is established with Duplex ultrasound when peak systolic velocity ratio (PSVR) is greater than 3 for any one level, or, if patients have multi-level disease, PSVR ≥ 2 at more than one level (i.e. sfa, pop) | ElP | Posted | Count of Units | Limbs | 1 day | Limbs | Limbs |
|
Through study completion, an average of 1 day.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | BlueDop Vascular Expert (BVE) | PAD assessment with BVE BVE: Participants will undergo BVE evaluation for assessing Peripheral Arterial Disease (PAD) |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Patrick Kelly | BlueDop Medical, Ltd. | +1 605 521 9831 | patrick@bluedopmedical.co.uk |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Feb 14, 2022 | Sep 3, 2024 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Nov 14, 2023 | Sep 3, 2024 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D058729 | Peripheral Arterial Disease |
| ID | Term |
|---|---|
| D050197 | Atherosclerosis |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Evaluation of BVE safety through the assessment of the risk and occurrence rates of AEs and SAEs |
| 1 day |
Evaluation of clinical equivalence of BVE testing performed by staff specifically trained on BVE who are not vascular technologists/specialists compared to BVE testing performed by vascular technologists/specialists. |
| 1 day |
| BVE Non-diagnostic Rate | Number of patients and/or limbs that could not be assessed by BVE. | 1 day |
| Manises |
| Valencia |
| 46940 |
| Spain |
| Clínica Universidad de Navarra | Madrid | 28027 | Spain |
| Hospital Doctor Peset | Valencia | 46017 | Spain |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Units | Counts |
|---|
| Participants |
|
| Limbs |
|
|
| Secondary | Determination of Presence or Absence of Significant PAD With BVE and ABPI | Evaluation of clinical equivalence through a binary result (either presence or absence of significant PAD) in BVE compared to a binary summary of ABPI. Significant PAD is established when ABPI index is <0.8. | ElP | Posted | Count of Units | Limbs | 1 day | Limbs | Limbs |
|
|
|
| Secondary | Number and Risk-classification of Adverse Events (AEs) and Serious Adverse Events (SAEs) | Evaluation of BVE safety through the assessment of the risk and occurrence rates of AEs and SAEs | Posted | Number | adverse events | 1 day |
|
|
|
| Other Pre-specified | Time Spent for Arterial Duplex, BVE and ABPI Vascular Assessment | Comparison of the time to perform a vascular assessment using arterial duplex, BVE, and ABPI (when available). | Posted | Mean | Standard Deviation | minutes | 1 day |
|
|
|
| Other Pre-specified | Determination of Presence or Absence of Significant PAD With BVE by Vascular and Non-vascular Experts | Evaluation of clinical equivalence of BVE testing performed by staff specifically trained on BVE who are not vascular technologists/specialists compared to BVE testing performed by vascular technologists/specialists. | Posted | Number | Proportion of cases with agreement | 1 day | Limbs | Limbs |
|
|
|
| Other Pre-specified | BVE Non-diagnostic Rate | Number of patients and/or limbs that could not be assessed by BVE. | This outcome was analyzed in the Enrollment population, not in the Eligible Population. The Eligible Population comprises the subset of enrolled patients who have at least one valid determination of PAD with both devices, and a limb without a valid PAD determination is considered analyzed if the other limb has a valid PAD determination. In the Enrollment Population we can find patients without any valid determination of PAD with BVE. | Posted | Count of Units | Limbs | 1 day | Limbs | Limbs |
|
|
|
| 0 |
| 187 |
| 0 |
| 187 |
| 0 |
| 187 |
The results and data obtained in the Clinical Trial shall be the exclusive property of the Sponsor, who reserves the right to use the results of this Trial to submit them to the authorities of any country.
| D002318 |
| Cardiovascular Diseases |
| D016491 | Peripheral Vascular Diseases |
| False Negatives |
|